MAM
Turkish Airlines launches partnership with German soccer club Borussia Dortmund
MUMBAI: Turkish Airlines has announced an agreement with BorussiaDortmund, champion in the 2010 and 2011 seasons of Germany‘s soccer league Bundesliga.
On 2 May 2013, Turkish Airlines and Borussia Dortmund (BVB) will meet to sign a three year agreement.
It represents a commitment for both sides and will involve joint activities and programs. Turkish Airlines will be the airline of choice for all BVB international flights. Turkish Airlines serves 12 German cities with roughly 250 flights a week. Then, from its hub in Istanbul, the airline offers connections that allow the team to travel across the world.
Turkish Airlines says that it is a natural partner for Borussia Dortmund, combining excellence in sports with excellence in aviation and service. The football club meanwhile stands for tradition, regional identity, hard work and successs – all principles that Turkish Airlines also values and strives to exhibit.
Turkish Airlines chairman Hamdi Topçu said, “We are excited to accompany Borussia Dortmund on its path towards success in the near future and are looking forward to a fruitful partnership.
“Turkish Airlines and Borussia Dortmund share a similar success story. Dortmund has a very notable set of players, many of them young and successful. The company also invests heavily in talent building. Several of the Borussia Dortmund players are members of both the German and Turkish national teams.”
Borussia Dortmund CEO Hans-Joachim Watzke said, “We are glad to have Turkish Airlines, a global brand as our partner. Turkish Airlines is a strong brand with obviously high quality and a first class service. We are looking forward to cooperate with Turkish Airlines and pleased, that they chose Borussia Dortmund as a strong partner to realize their goals.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
